Table 2.
Demographic and baseline characteristics
| Characteristics | 3 doses gE/AS01B (N = 30) | 3 doses gE/AS01E (N = 29) | 2 doses gE/AS01B (N = 31) | 3 doses saline (N = 30) | Total (N = 120) |
|---|---|---|---|---|---|
| Age, years | |||||
| Median (range) | 56.5 (20-70) | 58.0 (24-70) | 58.0 (42-68) | 59.5 (30-70) | 59.0 (20-70) |
| Sex, n (%) | |||||
| Male | 18 (60.0) | 20 (69.0) | 21 (67.7) | 19 (63.3) | 78 (65.0) |
| Ethnicity, n (%) | |||||
| White | 24 (80.0) | 24 (82.8) | 30 (96.8) | 22 (73.3) | 100 (83.3) |
| African/African American | 2 (6.7) | 2 (6.9) | 1 (3.2) | 1 (3.3) | 6 (5.0) |
| Asian | 1 (3.3) | 0 (0.0) | 0 (0.0) | 3 (10.0) | 4 (3.3) |
| Other | 3 (10.0) | 3 (10.3) | 0 (0.0) | 4 (13.3) | 10 (8.3) |
| Source of stem cells, n (%) | |||||
| Bone marrow | 3 (10.0) | 0 (0.0) | 2 (6.5) | 2 (6.7) | 7 (5.8) |
| Peripheral blood* | 27 (90.0) | 29 (100) | 29 (93.5) | 28 (93.3) | 113 (94.2) |
| Diagnosis leading to HCT, n (%) | |||||
| Myeloma | 18 (60.0) | 19 (65.5) | 20 (64.5) | 19 (63.3) | 76 (63.3) |
| Non-Hodgkin B-cell lymphoma | 8 (26.7) | 7 (24.1) | 7 (22.6) | 6 (20.0) | 28 (23.3) |
| Hodgkin lymphoma | 4 (13.3) | 2 (6.9) | 2 (6.5) | 1 (3.3) | 9 (7.5) |
| Non-Hodgkin T-cell lymphoma | 0 (0.0) | 1 (3.4) | 1 (3.2) | 4 (13.3) | 6 (5.0) |
| Acute myeloid leukemia | 0 (0.0) | 0 (0.0) | 1 (3.2) | 0 (0.0) | 1 (0.8) |
| Regimen before the current HCT, n (%) | |||||
| Myeloablative† | 28 (93.3) | 27 (93.1) | 28 (90.3) | 28 (93.3) | 111 (92.5) |
| Nonmyeloablative‡ | 2 (6.7) | 2 (6.9) | 3 (9.7) | 2 (6.7) | 9 (7.5) |
gE/AS01B, glycoprotein E/liposome-based adjuvant (50 µg MPL, 50 µg QS21); gE/AS01E, glycoprotein E/liposome-based adjuvant (25 µg MPL, 25 µg QS21); HCT, hematopoietic cell transplant.
*
Including apheresis.
†
With or without total body irradiation.
‡
Including one patient who received lenalidomide, zoledronic acid, and plerixafor.